| Předmět: |
|
| Zdroj: |
Drug Week; 9/16/2024, p2190-2190, 1p |
| Abstrakt: |
A recent study conducted by researchers from the University of Florida College of Medicine Jacksonville examined the utilization and outcomes of Digoxin Immune Fab (DIF) therapy for digoxin toxicity. Digoxin is commonly prescribed for congestive heart failure and atrial fibrillation, but it has a narrow therapeutic index and can easily lead to toxicity. The study found that DIF therapy was beneficial in limiting the duration of toxicity and reducing the length of stay in the intensive care unit for patients with digoxin toxicity. However, there were cases where DIF treatment was either underutilized or not indicated. The study highlights the need for appropriate utilization of DIF therapy in clinical practice. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
